Bioavailability of Levoketoconazole and Ketoconazole Tablets
Study Details
Study Description
Brief Summary
This is a phase 1, randomized, open-label, single-dose, two-period, two-sequence crossover study in healthy male and female subjects to evaluate the relative oral bioavailability of levoketoconazole tablets (the test drug) and ketoconazole tablets (the reference drug product).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 1 |
Detailed Description
This is a phase 1, randomized, open-label, single-dose, two-period, two-sequence crossover study in healthy male and female subjects to evaluate the relative oral bioavailability of levoketoconazole tablets (the test drug) and ketoconazole tablets (the reference drug product). Subjects will be randomized to receive a single oral dose of 150 mg levoketoconazole (Study Drug A) or a single oral dose of 200 mg ketoconazole (Study Drug B) in each period.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Levoketoconazole Levoketoconazole 150 mg |
Drug: Levoketoconazole
Levoketoconazole tablet
Other Names:
|
| Active Comparator: Ketoconazole Ketoconazole 200 mg |
Drug: Ketoconazole
Ketoconazole tablet
|
Outcome Measures
Primary Outcome Measures
- Ratio of geometric least squares means for AUClast of plasma levoketoconazole (2S,4R-ketoconazole) [24 hours]
Point estimates and 90 percent (%) confidence intervals (CIs) for the dose-normalized ratios of geometric least squares means between Test (levoketoconazole) and Reference (ketoconazole)
- Ratio of geometric least squares means for AUCinf of plasma levoketoconazole (2S,4R-ketoconazole) [24 hours]
Point estimates and 90 percent (%) confidence intervals (CIs) for the dose-normalized ratios of geometric least squares means between Test (levoketoconazole) and Reference (ketoconazole)
- Ratio of geometric least squares means for Cmax of plasma levoketoconazole (2S,4R-ketoconazole) [24 hours]
Point estimates and 90 percent (%) confidence intervals (CIs) for the dose-normalized ratios of geometric least squares means between Test (levoketoconazole) and Reference (ketoconazole)
Secondary Outcome Measures
- Terminal phase rate constant (λz) [24 hours]
Single-dose plasma PK parameters after a single administration of levoketoconazole and ketoconazole in the fasted state including λz
- Time to Maximum Plasma concentration (Tmax) [24 hours]
Single-dose plasma PK parameters after a single administration of levoketoconazole and ketoconazole in the fasted state including Tmax
- Lag-time (Tlag) [24 hours]
Single-dose plasma PK parameters after a single administration of levoketoconazole and ketoconazole in the fasted state including: Tlag
- Apparent systemic clearance (CL/F) [24 hours]
Single-dose plasma PK parameters after a single administration of levoketoconazole and ketoconazole in the fasted state including: CL/F
- The percentage of area under the plasma concentration-time curve extrapolated from time 0 to infinity as a percentage of total AUC (%AUCext) [24 hours]
Single-dose plasma PK parameters after a single administration of levoketoconazole and ketoconazole in the fasted state including: %AUCext
- Volume of Distribution (Vz/F) [24 hours]
Single-dose plasma PK parameters after a single administration of levoketoconazole and ketoconazole in the fasted state including: Vz/F
- Elimination half-life (T1/2) [24 hours]
Single-dose plasma PK parameters after a single administration of levoketoconazole and ketoconazole in the fasted state including: t½
- Incidence of adverse events (AEs) [35 days]
Incidence of Treatment-Emergent AEs (TEAEs), AEs of special interest, and Serious Adverse Events (SAEs)
Eligibility Criteria
Criteria
Inclusion Criteria:
-
18 to 55 years of age, inclusive, at time of consent.
-
Body mass index (BMI) between 18.0 and 32.0 kg/m2,inclusive.
-
In good general physical health as determined by absence of clinically significant medical history, physical examination findings, vital signs, clinical laboratory evaluations, and ECG measurements.
-
Has not consumed and agrees to abstain from taking any prescription drugs, dietary supplements including vitamins and herbal preparations, or non-prescription drugs for 14 days prior to clinical research unit (CRU) admission, during washout period, and through Follow-Up.
-
Has not consumed alcohol-containing beverages for 3 days prior to CRU admission and agrees not to consume alcohol through Follow-Up.
-
Is a nonsmoker (for at least 3 months) with negative urinary cotinine test at Screening and agrees to abstain from tobacco-and nicotine-containing products for the duration of the study.
Exclusion Criteria:
-
Evidence of any out-of-normal-range laboratory value at Screening that has not been reviewed, approved, and documented as Not Clinically Significant by the Investigator.
-
Concurrent medical illness that would interfere with the conduct of the study in the opinion of the Investigator.
-
History or presence of clinically significant cardiovascular, pulmonary, hematologic, endocrine, immunologic, dermatologic, neurologic, psychiatric, renal, hepatic, chronic respiratory, or gastrointestinal disease as judged by the Investigator.
-
Positive urine drug screen for drugs-of-abuse, including cocaine, tetrahydrocannabinol, opioids, benzodiazepines, amphetamines, and barbiturates,and/or positive urine screen for alcohol at Screening and CRU admission.
-
Treatment with an investigational drug within the longer of 30 days or five half-lives of the investigational drug preceding the first dose of study drug.
-
Positive for HIV, hepatitis B, and/or hepatitis C on Screening assessments.
-
Acute illness within 7 days of CRU admission.
-
Donated plasma within 7 days of drug administration.
-
Donated 1 or more pints of blood (or equivalent blood loss) within 30 days prior to drug administration.
-
History of caffeine consumption exceeding 8 cups coffee/day within 14 days prior to first dose, or consumption of any caffeine-or chocolate-containing products for 3 days prior to CRU admission each week.
-
Female subjects who are pregnant or lactating.
-
Males with hemoglobin less than 12.0 g/dL at Screening or CRU admission; Females with hemoglobin less than 11.0 g/dL at Screening or CRU admission
-
Had difficulties with swallowing whole tablets.
-
Body habitus preventing repeated venipuncture as required by protocol.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Pharmaceutical Research Associates, Inc. | Salt Lake City | Utah | United States | 84124 |
Sponsors and Collaborators
- Cortendo AB
Investigators
- Study Director: Xavier Valencia, MD, Cortendo AB
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- LKC101A